Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Pachyman treatment improves CD4+CD25+ Treg counts and serum interleukin 4 and interferon gamma levels in a mouse model of Kawasaki disease.

Authors: Chu, MP  Wang, D  Zhang, YY  Li, BQ  Zhou, AH  Chen, XW  Qian, Y 
Citation: Chu MP, etal., Mol Med Rep. 2012 May;5(5):1237-40. doi: 10.3892/mmr.2012.799. Epub 2012 Feb 20.
Pubmed: (View Article at PubMed) PMID:22367425
DOI: Full-text: DOI:10.3892/mmr.2012.799

The aim of this study was to explore the effect of pachyman, a mushroom extract, on CD4+CD25+ regulatory T cells (Tregs), serum interleukin 4 (IL-4) and interferon gamma (IFN-gamma) levels in a mouse model of Kawasaki disease. Lactobacillus casei cell wall extract was diluted to 1 mg/ml in PBS and administered to mice by intraperitoneal injection to establish a model of Kawasaki disease. Sixty female mice were used in this study, 40 of which were randomly assigned to a model (normal saline by gavage, n=20) or experimental group (200 mg/kg/day pachyman by gavage, n=20). The remaining 20 mice were disease and treatment-free, and were used as the control group. Compared to the control mice, mice in the model group exhibited a significantly lower percentage of CD4+CD25+ Tregs and significantly higher serum IL-4 and IFN-gamma levels (P<0.05). However, CD4+CD25+ Tregs significantly increased and IL-4 and IFN-gamma levels significantly decreased in experimental mice following pachyman treatment (P<0.05). Further analysis showed a negative correlation between CD4+CD25+ Tregs and IL-4/IFN-gamma levels (P<0.05). In conclusion, pachyman improves immune function in a mouse model of Kawasaki disease by upregulating CD4+CD25+ Tregs, which may inhibit the cytokine secretion of Th1 and Th2 cells.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 7829825
Created: 2014-01-28
Species: All species
Last Modified: 2014-01-28
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.